1
|
Li J, Liu Y, Li Y, Sun T, Xiang H, He Z. The Role of Gut Microbiota and Circadian Rhythm Oscillation of Hepatic Ischemia-Reperfusion Injury in Diabetic Mice. Biomedicines 2023; 12:54. [PMID: 38255161 PMCID: PMC10813792 DOI: 10.3390/biomedicines12010054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2023] [Revised: 12/11/2023] [Accepted: 12/19/2023] [Indexed: 01/24/2024] Open
Abstract
Circadian rhythm oscillation and the gut microbiota play important roles in several physiological functions and pathology regulations. In this study, we aimed to elucidate the characteristics of diabetic hepatic ischemia-reperfusion injury (HIRI) and the role of the intestinal microbiota in diabetic mice with HIRI. Hepatic ischemia-reperfusion injury surgery was performed at ZT0 or ZT12. The liver pathological score and the serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were analyzed to evaluate liver injury. We conducted an FMT experiment to examine the role of intestinal microbiota in diabetic mice with HIRI. The 16S rRNA gene sequencing of fecal samples was performed for microbial analysis. Our results showed that hyperglycemia aggravated HIRI in diabetic mice, but there was no diurnal variation seen in diabetic HIRI. We also demonstrated that there were significant alterations in the gut microbiota composition between the diabetic and control mice and that gut microbiota transplantation from diabetic mice had obvious harmful effects on HIRI. These findings provide some useful information for the future research of diabetic mice with HIRI.
Collapse
Affiliation(s)
| | | | | | | | - Hongbing Xiang
- Hubei Key Laboratory of Geriatric Anesthesia and Perioperative Brain Health, Wuhan Clinical Research Center for Geriatric Anesthesia, Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; (J.L.); (Y.L.); (Y.L.); (T.S.)
| | - Zhigang He
- Hubei Key Laboratory of Geriatric Anesthesia and Perioperative Brain Health, Wuhan Clinical Research Center for Geriatric Anesthesia, Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; (J.L.); (Y.L.); (Y.L.); (T.S.)
| |
Collapse
|
2
|
Zhang S, Yang L, Guo S, Hu F, Cheng D, Sun J, Li Y, Xu J, Sang H. Mannose binding lectin-associated serine protease-1 is a novel contributor to myocardial ischemia/reperfusion injury. Int J Cardiol 2023; 389:131193. [PMID: 37473815 DOI: 10.1016/j.ijcard.2023.131193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/05/2023] [Revised: 06/08/2023] [Accepted: 07/14/2023] [Indexed: 07/22/2023]
Abstract
BACKGROUND The lectin pathway has been demonstrated to play a critical role in the pathological process of myocardial ischemia/reperfusion injury (IRI). Mannose-binding lectin (MBL)-associated serine protease-1 (MASP-1), especially different from other components of the lectin pathway, mediates proinflammatory and procoagulant reactions independent of complement cascades. However, the role of MASP-1 in myocardial IRI remains unknown so far. METHODS Myocardial IRI was established with 45 min ischemia and 24 h reperfusion in mice. C1 inhibitor, as the natural inhibitor of MASP-1, was administrated at 20 IU/Kg via tail vein 5 min before surgical operation. Cardiac function and myocardial infarct size were assessed. Myocardial histology and fibrosis were evaluated by H&E and Masson staining, respectively. Deposition of MASP-1, expression of PAR-1/4 and neutrophil extracellular traps (NET) were investigated on myocardium tissue by IHC staining. Cell apoptosis was detected by TUNEL assay. Levels of myocardial enzymes and proinflammatory cytokines were determined by ELISA. RESULTS Inhibition of MASP-1 with C1 INH improved cardiac function and alleviated myocardium tissue injury (infarct size, enzymes, histology and fibrosis) after myocardial IRI. Deposition of MASP-1 and expression PAR-1, as well as NET formation in myocardial tissue were suppressed by MASP-1 inhibitor, while PAR-4 was elevated. Levels of apoptosis, HMGB-1 and IL-6 were lower after blocking MASP-1. Yet, IL-8 and TNF-α remained unchanged. CONCLUSIONS MASP-1, as a new contributor, played a critical role in myocardial IRI. Inhibition of MASP-1 protected myocardial tissue from IRI probably via regulation of PARs/NET pathway. This may provide a novel target strategy against myocardial IRI.
Collapse
Affiliation(s)
- Shengye Zhang
- Department of Cardiology, The first Affiliated Hospital, University of Zhengzhou, Zhengzhou, China
| | - Linjie Yang
- Department of Cardiovascular Surgery, The first Affiliated Hospital, University of Zhengzhou, Zhengzhou, China
| | - Shengcun Guo
- Department of Cardiology, The first Affiliated Hospital, University of Zhengzhou, Zhengzhou, China
| | - Fudong Hu
- Department of Cardiology, The first Affiliated Hospital, University of Zhengzhou, Zhengzhou, China
| | - Dong Cheng
- Department of Cardiology, The first Affiliated Hospital, University of Zhengzhou, Zhengzhou, China
| | - Jihong Sun
- Department of Cardiology, The first Affiliated Hospital, University of Zhengzhou, Zhengzhou, China
| | - Yunpeng Li
- Department of Cardiology, The first Affiliated Hospital, University of Zhengzhou, Zhengzhou, China
| | - Jing Xu
- Department of Cardiovascular Surgery, The first Affiliated Hospital, University of Zhengzhou, Zhengzhou, China.
| | - Haiqiang Sang
- Department of Cardiology, The first Affiliated Hospital, University of Zhengzhou, Zhengzhou, China.
| |
Collapse
|
3
|
Liu Q, Zhu Y, Li G, Guo T, Jin M, Xi D, Wang S, Liu X, Guo S, Liu H, Fan J, Liu R. Irisin ameliorates myocardial ischemia-reperfusion injury by modulating gut microbiota and intestinal permeability in rats. PLoS One 2023; 18:e0291022. [PMID: 37656700 PMCID: PMC10473488 DOI: 10.1371/journal.pone.0291022] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Accepted: 08/18/2023] [Indexed: 09/03/2023] Open
Abstract
Recently, myocardial ischemia-reperfusion (I/R) injury was suggested associated with intestinal flora. However, irisin has demonstrated beneficial effects on myocardial I/R injury, thus increasing interest in exploring its mechanism. Therefore, whether irisin interferes in gut microbiota and gut mucosal barrier during myocardial I/R injury was investigated in the present study. Irisin was found to reduce the infiltration of inflammatory cells and fracture in myocardial tissue, myocardial enzyme levels, and the myocardial infarction (MI) area. In addition, the data showed that irisin reverses I/R-induced gut dysbiosis as indicated by the decreased abundance of Actinobacteriota and the increased abundance of Firmicutes, and maintains intestinal barrier integrity, reduces metabolic endotoxemia, and inhibits the production of proinflammatory cytokines interleukin 1β (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor α (TNF-α). Based on the results, irisin could be a good candidate for ameliorating myocardial I/R injury and associated diseases by alleviating gut dysbiosis, endothelial dysfunction and anti-inflammatory properties.
Collapse
Affiliation(s)
- Qingqing Liu
- LinFen Central Hospital, LinFen, China
- Linfen Key Laboratory of Basic and Clinical Research on Coronary Heart Disease, Linfen Clinical Medical Research Center, LinFen, China
| | - Yu Zhu
- LinFen Central Hospital, LinFen, China
- Linfen Key Laboratory of Basic and Clinical Research on Coronary Heart Disease, Linfen Clinical Medical Research Center, LinFen, China
- School of Sport Medicine and Rehabilitation, Beijing Sport University, Beijing, China
| | - Guangyao Li
- LinFen Central Hospital, LinFen, China
- Linfen Key Laboratory of Basic and Clinical Research on Coronary Heart Disease, Linfen Clinical Medical Research Center, LinFen, China
| | - Tiantian Guo
- LinFen Central Hospital, LinFen, China
- Linfen Key Laboratory of Basic and Clinical Research on Coronary Heart Disease, Linfen Clinical Medical Research Center, LinFen, China
| | - Mengtong Jin
- LinFen Central Hospital, LinFen, China
- Linfen Key Laboratory of Basic and Clinical Research on Coronary Heart Disease, Linfen Clinical Medical Research Center, LinFen, China
| | - Duan Xi
- LinFen Central Hospital, LinFen, China
| | | | - Xuezhi Liu
- LinFen Central Hospital, LinFen, China
- Linfen Key Laboratory of Basic and Clinical Research on Coronary Heart Disease, Linfen Clinical Medical Research Center, LinFen, China
- Department of Cardiovascular Surgery, Linfen Central Hospital, Linfen, China
| | - Shuming Guo
- LinFen Central Hospital, LinFen, China
- Linfen Key Laboratory of Basic and Clinical Research on Coronary Heart Disease, Linfen Clinical Medical Research Center, LinFen, China
| | - Hui Liu
- LinFen Central Hospital, LinFen, China
- Linfen Key Laboratory of Basic and Clinical Research on Coronary Heart Disease, Linfen Clinical Medical Research Center, LinFen, China
- Department of Cardiovascular Surgery, Linfen Central Hospital, Linfen, China
| | - Jiamao Fan
- LinFen Central Hospital, LinFen, China
- Linfen Key Laboratory of Basic and Clinical Research on Coronary Heart Disease, Linfen Clinical Medical Research Center, LinFen, China
- Department of Cardiology, Linfen Central Hospital, Linfen, China
| | - Ronghua Liu
- LinFen Central Hospital, LinFen, China
- Linfen Key Laboratory of Basic and Clinical Research on Coronary Heart Disease, Linfen Clinical Medical Research Center, LinFen, China
| |
Collapse
|
4
|
Li J, Yin L, Chen S, Li Z, Ding J, Wu J, Yang K, Xu J. The perspectives of NETosis on the progression of obesity and obesity-related diseases: mechanisms and applications. Front Cell Dev Biol 2023; 11:1221361. [PMID: 37649550 PMCID: PMC10465184 DOI: 10.3389/fcell.2023.1221361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Accepted: 08/04/2023] [Indexed: 09/01/2023] Open
Abstract
Obesity is a disease commonly associated with urbanization and can also be characterized as a systemic, chronic metabolic condition resulting from an imbalance between energy intake and expenditure. The World Health Organization (WHO) has identified obesity as the most serious chronic disease that is increasingly prevalent in the world population. If left untreated, it can lead to dangerous health issues such as hypertension, hyperglycemia, hyperlipidemia, hyperuricemia, nonalcoholic steatohepatitis, atherosclerosis, and vulnerability to cardiovascular and cerebrovascular events. The specific mechanisms by which obesity affects the development of these diseases can be refined to the effect on immune cells. Existing studies have shown that the development of obesity and its associated diseases is closely related to the balance or lack thereof in the number and function of various immune cells, of which neutrophils are the most abundant immune cells in humans, infiltrating and accumulating in the adipose tissues of obese individuals, whereas NETosis, as a newly discovered type of neutrophil-related cell death, its role in the development of obesity and related diseases is increasingly emphasized. The article reviews the significant role that NETosis plays in the development of obesity and related diseases, such as diabetes and its complications. It discusses the epidemiology and negative impacts of obesity, explains the mechanisms of NETosis, and examines its potential as a targeted drug to treat obesity and associated ailments.
Collapse
Affiliation(s)
- Jinyu Li
- Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang University, Nanchang, China
- The First Clinical Medical College of Nanchang University, First Affiliated Hospital of Nanchang University, Nanchang, China
| | - Lijia Yin
- The First Clinical Medical College of Nanchang University, First Affiliated Hospital of Nanchang University, Nanchang, China
| | - Siyi Chen
- The First Clinical Medical College of Nanchang University, First Affiliated Hospital of Nanchang University, Nanchang, China
| | - Zelin Li
- The First Clinical Medical College of Nanchang University, First Affiliated Hospital of Nanchang University, Nanchang, China
| | - Jiatong Ding
- The Second Clinical Medical College of Nanchang University, Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Jiaqiang Wu
- The Second Clinical Medical College of Nanchang University, Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Kangping Yang
- The Second Clinical Medical College of Nanchang University, Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Jixiong Xu
- Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang University, Nanchang, China
- Jiangxi Clinical Research Center for Endocrine and Metabolic Disease, Nanchang, Jiangxi, China
- Jiangxi Branch of National Clinical Research Center for Metabolic Disease, Nanchang, Jiangxi, China
| |
Collapse
|
5
|
Inflammatory Response: A Crucial Way for Gut Microbes to Regulate Cardiovascular Diseases. Nutrients 2023; 15:nu15030607. [PMID: 36771313 PMCID: PMC9921390 DOI: 10.3390/nu15030607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Revised: 01/09/2023] [Accepted: 01/20/2023] [Indexed: 01/26/2023] Open
Abstract
Gut microbiota is the largest and most complex microflora in the human body, which plays a crucial role in human health and disease. Over the past 20 years, the bidirectional communication between gut microbiota and extra-intestinal organs has been extensively studied. A better comprehension of the alternative mechanisms for physiological and pathophysiological processes could pave the way for health. Cardiovascular disease (CVD) is one of the most common diseases that seriously threatens human health. Although previous studies have shown that cardiovascular diseases, such as heart failure, hypertension, and coronary atherosclerosis, are closely related to gut microbiota, limited understanding of the complex pathogenesis leads to poor effectiveness of clinical treatment. Dysregulation of inflammation always accounts for the damaged gastrointestinal function and deranged interaction with the cardiovascular system. This review focuses on the characteristics of gut microbiota in CVD and the significance of inflammation regulation during the whole process. In addition, strategies to prevent and treat CVD through proper regulation of gut microbiota and its metabolites are also discussed.
Collapse
|
6
|
Borshchev YY, Burovenko IY, Karaseva AB, Minasian SM, Protsak ES, Borshchev VY, Semenova NY, Borshcheva OV, Suvorov AN, Galagudza MM. Probiotic Therapy with Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis Results in Infarct Size Limitation in Rats with Obesity and Chemically Induced Colitis. Microorganisms 2022; 10:2293. [PMID: 36422363 PMCID: PMC9698902 DOI: 10.3390/microorganisms10112293] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2022] [Revised: 11/13/2022] [Accepted: 11/17/2022] [Indexed: 11/04/2023] Open
Abstract
In this study, we investigated the effect of three different probiotics, namely, a combination of Lactobacillus acidophilus (LA-5) and Bifidobacterium animalis subsp. lactis (BB-12), Saccharomyces boulardii, and Enterococcus faecium L3 on myocardial infarct size in rats with diet-induced obesity (DIO) and chemically-induced colitis (CIC). Potential associations between the effects of probiotics on myocardial ischemia-reperfusion injury and gut microbiome patterns as well as the serum levels of pro- and anti-inflammatory cytokines, lipopolysaccharide, and short chain fatty acids were also studied. Intragastric administration of lyophilized Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis at a dose of 1.2 × 108 CFU/mL for 15 days resulted in myocardial infarct size reduction in rats with DIO, CIC, and antibiotic-induced dysbiosis. This cardioprotective effect was associated with specific changes in cytokine concentrations, namely reduced levels of IL-1β, TNF-α, IL-2, and IL-8. At the same time, the use of Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis was accompanied by a significant reduction in lipopolysaccharide level, suggesting normalization of intestinal epithelial barrier permeability. However, the cardioprotective effect of Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis is not secondary to improved healing of the intestinal mucosa in CIC, as evidenced by the lack of difference in histopathological scores.
Collapse
Affiliation(s)
- Yury Y. Borshchev
- Research Department of Toxicology, Institute of Experimental Medicine, Almazov National Medical Research Centre, 43 Dolgoozernaya Street, 197371 Saint Petersburg, Russia
| | - Inessa Y. Burovenko
- Research Department of Toxicology, Institute of Experimental Medicine, Almazov National Medical Research Centre, 43 Dolgoozernaya Street, 197371 Saint Petersburg, Russia
| | - Alena B. Karaseva
- Department of Molecular Microbiology, Institute of Experimental Medicine, 12 Academic Pavlov’s Street, 197376 Saint Petersburg, Russia
| | - Sarkis M. Minasian
- Department of Microcirculation and Myocardial Metabolism, Institute of Experimental Medicine, Almazov National Medical Research Centre, 15B Parkhomenko Street, 194021 Saint Petersburg, Russia
| | - Egor S. Protsak
- Research Department of Toxicology, Institute of Experimental Medicine, Almazov National Medical Research Centre, 43 Dolgoozernaya Street, 197371 Saint Petersburg, Russia
| | - Victor Y. Borshchev
- Department of Pathophysiology with Clinical Pathophysiology Course, Pavlov First Saint Petersburg State Medical University, 6–8 Lev Tolstoy Street, 197022 Saint Petersburg, Russia
| | - Natalia Y. Semenova
- Research Department of Pathology, Institute of Experimental Medicine, Almazov National Medical Research Centre, 43 Dolgoozernaya Street, 197371 Saint Petersburg, Russia
| | - Olga V. Borshcheva
- Research Department of Toxicology, Institute of Experimental Medicine, Almazov National Medical Research Centre, 43 Dolgoozernaya Street, 197371 Saint Petersburg, Russia
| | - Alexander N. Suvorov
- Department of Molecular Microbiology, Institute of Experimental Medicine, 12 Academic Pavlov’s Street, 197376 Saint Petersburg, Russia
- Department of Fundamental Problems of Medicine and Medical Technologies, Saint Petersburg State University, 7/9 Universitetskaya Embankment, 199034 Saint Petersburg, Russia
| | - Michael M. Galagudza
- Department of Microcirculation and Myocardial Metabolism, Institute of Experimental Medicine, Almazov National Medical Research Centre, 15B Parkhomenko Street, 194021 Saint Petersburg, Russia
- Department of Pathophysiology with Clinical Pathophysiology Course, Pavlov First Saint Petersburg State Medical University, 6–8 Lev Tolstoy Street, 197022 Saint Petersburg, Russia
| |
Collapse
|
7
|
Zhang F, Li Y, Wu J, Zhang J, Cao P, Sun Z, Wang W. The role of extracellular traps in ischemia reperfusion injury. Front Immunol 2022; 13:1022380. [PMID: 36211432 PMCID: PMC9533173 DOI: 10.3389/fimmu.2022.1022380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2022] [Accepted: 08/31/2022] [Indexed: 11/29/2022] Open
Abstract
In response to strong signals, several types of immune cells release extracellular traps (ETs), which are web-like structures consisting of DNA decorated with various protein substances. This process is most commonly observed in neutrophils. Over the past two decades, ET formation has been recognized as a unique mechanism of host defense and pathogen destruction. However, the role of ETs in sterile inflammation has only been studied extensively in recent years. Ischemia reperfusion injury (IRI) is a type of sterile inflammatory injury. Several studies have reported that ETs have an important role in IRI in various organs. In this review, we describe the release of ETs by various types of immune cells and focus on the mechanism underlying the formation of neutrophil ETs (NETs). In addition, we summarize the role of ETs in IRI in different organs and their effects on tumors. Finally, we discuss the value of ETs as a potential therapeutic target for organ IRI and present possible challenges in conducting studies on IRI-related ETs as well as future research directions and prospects.
Collapse
Affiliation(s)
- Feilong Zhang
- Department of Urology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China
- Institute of Urology, Capital Medical University, Beijing, China
| | - Yuqing Li
- Department of Urology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China
- Institute of Urology, Capital Medical University, Beijing, China
| | - Jiyue Wu
- Department of Urology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China
- Institute of Urology, Capital Medical University, Beijing, China
| | - Jiandong Zhang
- Department of Urology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China
- Institute of Urology, Capital Medical University, Beijing, China
| | - Peng Cao
- Department of Urology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China
- Institute of Urology, Capital Medical University, Beijing, China
| | - Zejia Sun
- Department of Urology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China
- Institute of Urology, Capital Medical University, Beijing, China
| | - Wei Wang
- Department of Urology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China
- Institute of Urology, Capital Medical University, Beijing, China
- *Correspondence: Wei Wang,
| |
Collapse
|